跳至主要内容
临床试验/JPRN-UMIN000008780
JPRN-UMIN000008780已完成未知

An Efficacy Study of Esomeprazole in Patients with Reflux Esophagitis Poorly Responsive to Lansoprazole - An Efficacy Study of Esomeprazole in Patients with Reflux Esophagitis Poorly Responsive to Lansoprazole (CHANGE-L Study)

Research Organization for Gastroenterological Disease Treatment0 个研究点目标入组 200 人开始时间: 2012年12月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1) Patients with a history of hypersensitivity to the study drugs. (2) Patients with a history of digestive tract resection or vagotomy. (3) Patients with warning findings such as vomiting, gastrointestinal hemorrhage (including findings such as hematemesis, melena, and anemia) and acute weight loss. (4) Patients with concurrent peptic ulcer (excluding the scarred stage). (5) Patients with a past or current history of any of the following diseases: Zollinger-Ellison syndrome, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), esophageal stenosis, esophageal achalasia, malabsorption, or cerebrovascular disorder such as cerebral hemorrhage and cerebral infarction. (6) Patients treated for H. pylori eradication within 6 months before the time of eligibility check. (7) Patients who may have difficulty participating in the study owing to serious complications such as liver, renal, or cardiac diseases. (8) Patients with a confirmed or possible malignancy. (9) Women who are pregnant, lactating, or possibly pregnant. (10) Patients who are on proton pump inhibitors other than lansoprazole. (11) Patients who need to continue treatment with drugs for which interactions with the study drugs are anticipated. (12) Patients who are on or need to continue treatment with drugs that are assumed to have an effect on study results. *However, patients may be enrolled in the study if such drugs are interrupted for 1 week prior to the investigation of the symptoms or are switched to other treatment. (13) Patients who are determined by the investigator or subinvestigator to be not suitable to be enrolled in the study due to other reasons.

研究者

发起方
Research Organization for Gastroenterological Disease Treatment

相似试验